From the aforementioned studies, inactivation or loss of function aids in cell proliferation suggesting that the patient in this study with AML-M1 subtype might have a proliferative advantage as extensive expression of NOTCH1 especially in M1 and M0 – AML patients with simultaneous expression of CD7 which is a marker for immaturity was observed that reflects in a poor overall survival rate [31]. The gene discussed is NOTCH1; the disease is acute myeloid leukemia.